IDEXX Laboratories Stock Hits Day Low of $614.25 Amid Price Pressure

IDEXX Laboratories, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, experienced a notable decline of 4.59% on March 5, 2026. The stock reached an intraday low of USD 614.25, reflecting a challenging trading day for the company. In terms of performance metrics, IDEXX has shown a year-to-date decline of 8.52%, contrasting with the S&P 500's modest gain of 0.35%. Over the past week, the stock has decreased by 6.33%, while its one-month performance stands at a loss of 3.83%. However, on a yearly basis, IDEXX has outperformed the broader market, boasting a return of 41.55% compared to the S&P 500's 18.89%. The company maintains a strong financial position, highlighted by a high return on capital employed (ROCE) of 54.00% and a low debt-to-EBITDA ratio of 0.75 times. IDEXX's operational efficiency is further underscored by a robust inventory turnover ratio of 4.31 times and a significant operating cash flow of USD 1,178.06 million. With a market capitalization of USD 64,696 million, IDEXX continues to be a key player in its industry despite the recent stock fluctuations.